OneAscent Financial Services LLC Invests $200,000 in Guardant Health, Inc. (NASDAQ:GH)

OneAscent Financial Services LLC acquired a new position in shares of Guardant Health, Inc. (NASDAQ:GH) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 5,593 shares of the company’s stock, valued at approximately $200,000.

A number of other large investors also recently modified their holdings of GH. Captrust Financial Advisors lifted its stake in shares of Guardant Health by 33.2% in the second quarter. Captrust Financial Advisors now owns 1,087 shares of the company’s stock valued at $44,000 after buying an additional 271 shares during the period. Baird Financial Group Inc. lifted its position in shares of Guardant Health by 2.1% in the 3rd quarter. Baird Financial Group Inc. now owns 14,580 shares of the company’s stock worth $785,000 after acquiring an additional 296 shares during the period. Public Employees Retirement System of Ohio grew its holdings in shares of Guardant Health by 0.8% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 48,907 shares of the company’s stock worth $2,633,000 after purchasing an additional 385 shares in the last quarter. Xponance Inc. grew its holdings in shares of Guardant Health by 3.5% during the 1st quarter. Xponance Inc. now owns 13,498 shares of the company’s stock worth $316,000 after purchasing an additional 461 shares in the last quarter. Finally, Assetmark Inc. increased its position in shares of Guardant Health by 12.1% during the first quarter. Assetmark Inc. now owns 4,549 shares of the company’s stock valued at $107,000 after purchasing an additional 492 shares during the period. 92.65% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Kumud Kalia sold 2,125 shares of Guardant Health stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $32.59, for a total value of $69,253.75. Following the sale, the insider now owns 7,813 shares of the company’s stock, valued at approximately $254,625.67. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 6.20% of the company’s stock.

Guardant Health Trading Down 4.0 %

GH opened at $29.53 on Friday. Guardant Health, Inc. has a twelve month low of $20.67 and a twelve month high of $62.75. The firm has a market cap of $3.48 billion, a PE ratio of -6.01 and a beta of 0.87. The company has a debt-to-equity ratio of 3.89, a quick ratio of 6.65 and a current ratio of 6.96. The firm’s fifty day moving average is $36.60 and its two-hundred day moving average is $31.42.

Guardant Health (NASDAQ:GH) last announced its earnings results on Thursday, August 3rd. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($1.25) by $0.58. The firm had revenue of $137.15 million for the quarter, compared to the consensus estimate of $129.44 million. Guardant Health had a negative net margin of 99.62% and a negative return on equity of 427.89%. The business’s quarterly revenue was up 25.7% on a year-over-year basis. During the same period last year, the company posted ($2.25) EPS. Equities research analysts anticipate that Guardant Health, Inc. will post -3.9 EPS for the current year.

Wall Street Analyst Weigh In

GH has been the topic of several recent research reports. Morgan Stanley decreased their target price on shares of Guardant Health from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 7th. Piper Sandler boosted their price target on Guardant Health from $30.00 to $40.00 and gave the company a “neutral” rating in a research note on Tuesday, August 8th. William Blair reiterated an “outperform” rating on shares of Guardant Health in a research note on Friday, September 8th. Finally, Citigroup increased their target price on shares of Guardant Health from $40.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, August 4th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, Guardant Health currently has an average rating of “Moderate Buy” and an average price target of $56.87.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360; Guardant360 LDT; Guardant360 CDx; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.